The QualityStocks Daily Thursday, December 9th, 2021

Today's Top 3 Investment Newsletters

MarketClub Analysis(IINN) $4.9500 +84.01%

QualityStocks(ZNOG) $0.3189 +41.73%

RedChip(MYIDF) $0.3201 +41.12%

The QualityStocks Daily Stock List

Digatrade Financial Corp. (DIGAF)

QualityStocks, Wall Street Mover, Stock Commander, PoliticsAndMyPortfolio, Penny Picks, MoneyTV and Damn Good Penny Picks reported earlier on Digatrade Financial Corp. (DIGAF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Digatrade Financial Corp. is a global digital asset exchange and blockchain development services company. It engages in the licensing, development, and branding of a digital exchange trading platform and a peer to peer electronic payment processing network for enabling users to trade fiat and alternative currencies. Basically, DIGATRADE is a Digital Asset, Currency (Bitcoin) Exchange, and Internet Financial Services Company owned and operated by Digatrade Financial Corp.

Digatrade Financial is based in Vancouver, British Columbia. Formed in 2000, the Company lists on the OTC Markets Group’s OTCQB.

Digatrade Financial provides operational support specializing in web-based digital currency exchange and transaction services for the cryptographic digital currencies. This includes Bitcoin and other alternative digital coins. The Company provides a user-friendly, secure, and affordable platform to purchase and sell Bitcoin and other digital assets. Digatrade provides a 24-hour online platform. This platform provides the automated matching of orders between its registered members.

The proprietary Digatrade trading and matching engine manages high volume, high throughput, and low latency trading. Furthermore, this engine features blended multi-currency settlement in addition to real time FX pricing and risk management fully powered by ANX Technologies. The order engine delivers pre-scan indicative pricing. Users can choose to either fix the quantity of Bitcoins or fix the price paid for every order.

Digatrade Financial previously announced the execution of a definitive agreement with No Limits Consulting Ltd. (d/b/a: ANX International, ANX Technologies & ANXPRO) based in Hong Kong. Under new financial terms, Digatrade has re-positioned itself to continue its development with its core digital asset exchange platform. This is while centering on the implementation of new Initial Digital Offerings (IDO's) for institutional customers, marketing, and brand awareness.

Digatrade has launched the Digatrade OTC Trade Desk. The new Digatrade Over-the-Counter (OTC) trading service will let KYC verified customers to complete trades outside the online liquidity order book at competitive market prices.

At present, Digatrade Financial is developing a number of new technologies for the Digatrade Core 2.0 Digital Asset Trading Platform. In addition, the Company is seeking more new opportunities and partners for growth as Bitcoin (BTC) continues to grow in value with a market capitalization now surpassing $23.5 Billion.

Digatrade Financial Corp. (DIGAF), closed Thursday’s trading session at $0.0035, up 45.8333%, on 15,324,062 volume. The average volume for the last 3 months is 15.324M and the stock's 52-week low/high is $0.0012/$0.0318.

All For One Media Corp. (AFOM)

Small Cap Firm, QualityStocks, Penny Stock Prodigy, The FrontPageStocks, DSR News, InvestorSoup, Jet-Life Penny Stocks, Penny Stock Craze, Penny Stock Finder, Penny Stock Hub, Beacon Equity Research, Penny Stocks Finder, Winston Small Cap, PHUB News, ProTrader, Stock Preacher, SuperStockTips and Penny Stock Titans reported earlier on All For One Media Corp. (AFOM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

All For One Media Corp. is a tween marketing company listed on the OTC Markets’ OTCQB. Named “Generation I” for "Internet," this generation's tweens represent the first demographic to have had only known life with the Internet and social media. Essentially, All For One Media is a marketing brand changing the mindset of tweens that bullying is unacceptable. All For One Media has its head office in Mount Kisco, New York.

The Company is working to make the transition from a development stage corporation creating and acquiring media assets to a content provider launching many initiatives marketed to its core tween demographic. Its goal is to capitalize on a broad variety of potential revenue streams.

All For One Media, through entertainment, is working to deliver a message that will resonate with kids to impact the epidemic of bullying and cyber-bullying. In addition, it is working to help individuals who have been affected by bullying to deal with it in a positive and constructive manner.

All For One Media has produced Drama Drama (f/k/a "Crazy For the Boys"). Drama Drama is a full length coming of age musical dramedy. It features Groovy Tuesday music and choreography. This film tells the story of five high school girls from five very different cliques who must work together to run their school’s anti-bullying organization. The film features original pop songs pertaining to peer pressure, unrequited love, and teen angst. The expectation is that Drama Drama will generate revenues from numerous sources.

The Company has completed production of Drama Drama. It has started to screen the movie for buyers. Moreover, it engaged William Morris/Endeavor Content (WME) as the exclusive sales agent for the film. WME represents artists across all media platforms, particularly movies, television, music, theatre, digital and publishing.

All for One Media is making plans to commence group activities for the launch of the band "Drama Drama" concurrent to the release of the movie. The release of a full-length film used to promote the launch of a pop group is an industry first. The Company has also started negotiations with a number of major record labels for distribution of the film soundtrack.

All For One Media Corp. (AFOM), closed Thursday’s trading session at $0.0006, up 50%, on 202,707,560 volume. The average volume for the last 3 months is 202.708M and the stock's 52-week low/high is $0.0003/$0.0049.

Zion Oil & Gas, Inc. (ZNOG)

We reported earlier on Zion Oil & Gas, Inc. (ZNOG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Zion Oil & Gas, Inc. operates as an oil and gas exploration company in Israel. It explores for oil and gas onshore in Israel on its 99,000-acre Megiddo-Jezreel license area. Fundamentally, it is exploring for Israel’s Political and Economic Independence. Established in 2000, Zion Oil & Gas has its corporate headquarters in Dallas, Texas. It also has its Israel office in Caesarea. The Company’s shares trade on the OTCQX Best Market.

Zion Oil & Gas’ vision is to find oil and/or natural gas in Israel. The Company’s Founder and Chairman, Mr. John Brown, provides the broad vision and goals for Zion Oil & Gas. The Company says that the initiatives taken by its Management as it explores for oil and gas in Israel are founded on modern science and good business practices. Zion’s oil and gas exploration activities are supported by suitable geological, geophysical, as well as other science-based studies and surveys.

Mr. Brown has wide-ranging management, marketing, and sales experience, serving as Corporate Director of Purchasing at GTE Valeron, a subsidiary of GTE Corporation from 1966 to 1986. He was Corporate Director of Procurement at Magnetek, Inc. during 1988-89. Until 2012, Mr. Brown was also an Officer and Director of M&B Holding, Inc.

Zion Oil & Gas previously announced the departure of a drilling rig and equipment from Constanta, Romania and en route to Haifa, Israel. The Company expected the rig to reach the port of Haifa, Israel by November 13, 2020. Upon customs clearance, the crew was scheduled to satisfy certain protocols required by Israel, and, without unforeseen circumstances, Zion Oil & Gas expects to spud the Megiddo-Jezreel #2 well at its present well location near Bet She'an by early to mid-December 2020. The Company said that there is an aggressive drilling schedule planned on the Megiddo-Jezreel #2 (MJ02) well location.

Zion Oil & Gas, Inc. (ZNOG), closed Thursday’s trading session at $0.3189, up 41.7333%, on 6,899,171 volume. The average volume for the last 3 months is 6.899M and the stock's 52-week low/high is $0.111/$1.20.

PCT Ltd (PCTL)

We reported earlier on PCT Ltd (PCTL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PCT Ltd (OTC: PCTL) is a holding firm that is focused on designing, developing, manufacturing and licensing environmentally safe solutions globally.

The firm has its headquarters in Little River, South Carolina and was incorporated in 1986, on February 27th. Prior to its name change in February 2018, the firm was known as Bingham Canyon Corporation. It operates as part of the health and personal care stores industry. The firm has eighty-eight companies in its corporate family and serves consumers in the United States.

The company, through its Paradigm Convergence Technologies Corp subsidiary, offers solutions for social service providers which allow them to optimize their business operations. It markets new technologies and products for the oil and gas, hotel and tourism, education, food services, agriculture and healthcare industries, through various avenues.

The enterprise’s products include a mild surfactant degreaser and detergent known as Catholyte, which is utilized for janitorial cleaning purposes; and a sanitizer/disinfectant microbiocide dubbed Hydrolyte, which can be used in various institutional facilities, including schools, correctional facilities, hotels, nursing homes and hospitals. This microbiocide can be used to disinfect and sanitize water in industrial waste-water systems and in private and public water systems, eliminate sulfate reducing bacteria in gas and oil wells, sanitize food processing and disinfect crops pre-and post-harvest. Hydrolyte also has applications in animal husbandry.

The firm recently announced that it had developed an eco-friendly solution for the oil and gas industry dubbed the Nano-Catholyte. The solution, which makes the process to recover oil more efficient, has no toxic effect to the environment. Its introduction to the market will not only bring in additional revenue into the firm but also boost investments into the firm.

PCT Ltd (PCTL), closed Thursday’s trading session at $0.0232, up 26.087%, on 7,834,596 volume. The average volume for the last 3 months is 7.835M and the stock's 52-week low/high is $0.0075/$0.03425.

Pasithea Therapeutics (KTTA)

AwesomeStocks, QualityStocks, MarketClub Analysis, Broad Street, StockWireNews, StockStreetWire, Small Cap Firm and Fierce Analyst reported earlier on Pasithea Therapeutics (KTTA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pasithea Therapeutics Corp (NASDAQ: KTTA) is a biotechnology firm that is engaged in conducting research and discovering treatments for neurological and psychiatric disorders.

The firm has its headquarters in Miami Beach, Florida and was incorporated in May 2020 by Yassine Bendiabdallah. It serves consumers around the globe.

The company’s long-term objective is to translate research into clinic-ready medications. It is led by top immunologists from Stanford University. The company’s academic research is led by a renowned psychiatric academic at King’s College London. Its secondary operations are focused on establishing mobile clinics and anti-depression clinics across the United Kingdom and the United States, using trained pharmacists to administer ketamine infusions intravenously.

Epidemiological data shows that neuropsychiatric disorders are some of the most devastating and prevalent ailments, and yet, remain poorly treated. The enterprise has partnered with 2 successful clinics, i.e. Zen Healthcare and The IV Doc, for immediate exposure in various locations across the United States and the United Kingdom. Zen Healthcare has 3 central London clinics based in Knightsbridge, Holborn and Marylebone. In the U.S., The IV Doc is a leading operator of mobile clinics. The enterprise’s partnership with IV Doc will allow it to gain widespread distribution as well as rapid expansion and exposure.

The firm has expanded the access of its IV ketamine treatment to patients in Nevada and Florida, which will help close the treatment gap. This move will not only benefit patients but also bring in more investments and revenues into the firm, which will be good for its growth.

Pasithea Therapeutics (KTTA), closed Thursday’s trading session at $2.58, up 0.78125%, on 893,599 volume. The average volume for the last 3 months is 851,409 and the stock's 52-week low/high is $2.10/$8.50.

Two Hands Corp (TWOH)

Penny Stock General, Shiznit Stocks, QualityStocks, StockRockandRoll, Penny Stock 101, PennyStockLocks, Penny Stock Titans, Profitable Trader Authority, OTCtipReporter, Penny Picks, PennyStockScholar, Damn Good Penny Picks, Small Cap Firm, Fierce Analyst, Stock Commander, PennyStockProphet, StockWireNews, GrowthPennyStocks, Penny Pick Finders, BeatPennyStocks, StockOnion, Buzz Stocks, Epic Stock Picks, Monster Alerts, HotOTC, Wolf of Penny Stocks, Make Penny Stocks Great Again, MicroCapDaily, MassiveStockProfits, Insider Financial, InvestorSoup, Beacon Equity Research, Penny Stock Finder, ProTrader, Stock Preacher, StockHideout, StockStreetWire, Penny Stock Craze, OTCMagic, Penny Stock 106, Penny Stock Prodigy, PennyStockLocks.com, Explicit Penny Picks, Wealth Insider Alert and Winston Small Cap reported earlier on Two Hands Corp (TWOH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Two Hands Corp (OTC: TWOH) is a custom application development firm that is focused on the research and development of software applications.

The firm has its headquarters in Mississauga, Canada and was incorporated in 2009, on April 3rd by Doug Clark. Prior to its name change in September 2016, the firm was known as Innovative Product Opportunities Inc. It serves consumers in Canada.

The enterprise oversees the research, planning, pricing, creative development, tracking and deployment of its diversified solutions to firms in North America. One of its divisions, Gocart.city, is an online grocery delivery marketplace. The division is focused on curating and delivering specialty foods and the freshest produce in Southern Ontario. The enterprise’s other on-demand branches include Cuore Food services and Grocery Originals. Cuore Food operates as its wholesale food distribution branch. Grocery Originals is the firm’s brick-and-mortar grocery store, situated in Mississauga Ontario at the site of the firm’s warehouse. In addition to this, the enterprise offers an encrypted messaging application dubbed Two Hands Gone. Furthermore, it provides fresh-cut, individually packaged vegetables and fruits; Italian themed products like wine, coffee, tea, desserts, pasta and oils; specialized foods, which include gluten-free, artisan and health conscience items; and accessories like aprons, candles, table clothes, tableware and plates.

The company is focused on expanding into new locations, growing its grocery category to more than 2700 items as well as its customer base. In addition to this, it is focused on expanding its delivery area to better meet its customer demand.

Two Hands Corp (TWOH), closed Thursday’s trading session at $0.00115, off by 4.1667%, on 38,230,088 volume. The average volume for the last 3 months is 38.23M and the stock's 52-week low/high is $0.0007/$0.0097.

Beasley Broadcast Group (BBGI)

The Online Investor, MarketBeat, StreetInsider, InvestorPlace, Marketbeat.com, Wall Street Resources, TraderPower, StockHotTips and SmallCapInvestor.com reported earlier on Beasley Broadcast Group (BBGI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Beasley Broadcast Group Inc. (NASDAQ: BBGI) (FRA: BZS) is a radio broadcasting firm that is focused on the operation of radio stations.

The firm has its headquarters in Naples, Florida and was incorporated in 1961 by George G. Beasley. It serves consumers in the United States.

The company’s main source of revenue is the sale of advertising. Its subsidiaries include Team Renegades LLC, Renegades Holdings Inc., OutlawsXP Inc., Beasley Media Group Licenses LLC, Beasley Media Group and Beasley Mezzanine Holdings LLC.

The enterprise operates and owns AM and FM radio stations in mid-sized and large markets. These markets include West Palm Beach-Boca Raton and Miami-Fort Lauderdale in Florida; Tampa-Saint Petersburg; Philadelphia in Panama; Las Vegas in Nevada; Greenville-New Bern-Jacksonville and Fayetteville in New Caledonia; Fort Myers-Naples; Charlotte; Boston in Morocco; Morristown; Augustaand Atlanta in Gabon; and Wilmington in Germany. It offers management services to 2 radio stations in Las Vegas, Nevada. The enterprise also offers digital marketing and advertising solutions across the U.S. via its radio broadcast and digital operations. In addition to this, it provides national and local advertisers integrated marketing solutions across event, digital and audio platforms. Furthermore, the enterprise operates an e-sports team known as Houston Outlaws, which competes in the Overwatch League.

The firm recently announced its latest financial results which show significant increases in its net revenues and healthy growth in Wilmington, Tampa, Philadelphia, New Jersey, Las Vegas, Atlanta, Boston and Detroit, among others. Currently, it is focused on building its e-sports portfolio and looking for new ways to drive profitable long-term revenue growth.

Beasley Broadcast Group (BBGI), closed Thursday’s trading session at $2.01, off by 3.3654%, on 58,618 volume. The average volume for the last 3 months is 58,614 and the stock's 52-week low/high is $1.39/$3.42.

Azincourt Energy (AZURF)

SmallCapNetwork, OTCBB Journal, Investiv and Broad Street reported earlier on Azincourt Energy (AZURF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Azincourt Energy Corp (OTCQB: AZURF) (FRA: AOU2) is an exploration and development firm that is focused on the acquisition, exploration and development of alternative energy/fuel properties which possess cobalt, lithium, uranium and other elements.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2011, on April 7th. Prior to its name change in October 2017, the firm was known as Azincourt Uranium Inc. It serves the fuel energy and alternative energy sectors in Canada.

The company’s expanding focus will allow it to grow its evaluation in correlation to fuel and macro energy trends. Currently, uranium for the nuclear industry and battery metals like lithium, graphite, manganese, nickel and cobalt are at the forefront of a changing focus in energy development. The company is actively pursuing projects which position it for growth in the energy sector.

The enterprise is carrying out exploration activities on the ELC Project in Peru and the East Preston Project in the province of Saskatchewan, Canada. The former project comprises of roughly 6 Escalara project concessions which cover a combined area of about 5,500 hectares for volcanic hosted superficial/supergene lithium and uranium on the Picotani Plateau in Peru. The latter project is a uranium project in the Athabasca Basin in Canada. The project has offset breaks in the vicinity of interpreted fault lineaments targets for uncomformity uranium deposits.

The firm recently entered into an option agreement with ValOre Metals Corp to acquire 75% interest in the Hatchet Lake Uranium project. This move will bring in more investors into the firm as well as boost its revenues.

Azincourt Energy (AZURF), closed Thursday’s trading session at $0.0595, up 0.847458%, on 60,811 volume. The average volume for the last 3 months is 60,811 and the stock's 52-week low/high is $0.02544/$0.1423.

Vyne Therapeutics (VYNE)

QualityStocks, The Online Investor and MarketBeat reported earlier on Vyne Therapeutics (VYNE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vyne Therapeutics Inc. (NASDAQ: VYNE) is a pharmaceutical firm that is engaged in the development and commercialization of therapeutics for dermatological indications.

The firm has its headquarters in Bridgewater, New Jersey and was incorporated in 2003. Prior to its name change in September 2020, the firm was known as Menlo Therapeutics Inc. It serves consumers around the globe.

The company develops products that’ll help improve the lives of patients with dermatological ailments. It is also working to solve some of today’s most difficult therapeutic challenges by questioning traditional assumptions and finding better solutions to said challenges. It develops its solutions using its Molecule Stabilizing proprietary technology.

The enterprise’s product pipeline comprises of a combination of tofacitinib dubbed FMX114, which is in preclinical trial and has been developed to treat mild-moderate atopic dermatitis; and a topical combination foam known as FCD105, which has concluded phase 2 clinical trials evaluating its effectiveness in treating moderate-severe acne vulgaris. It also develops Zilxi, which is indicated for the treatment of inflammation lesions of papulopustular rosacea in adults. In addition to this, the enterprise develops a topical minocycline dubbed Amzeeq, which is utilized in the treatment of inflammatory lesions of non-nodular acne vulgaris in patients aged 9 and older.

The company recently announced its latest financial results, with its CEO noting that the firm is now fully focused on the development of next-generation therapeutics indicated for the treatment of various immuno-inflammatory ailments. In addition to this, it is focused on creating shareholder value.

Vyne Therapeutics (VYNE), closed Thursday’s trading session at $1.38, up 14.0496%, on 4,486,596 volume. The average volume for the last 3 months is 4.408M and the stock's 52-week low/high is $0.90/$13.20.

Computer Task Group, Inc. (CTG)

Streetwise Reports, Marketbeat.com, StreetInsider, MarketBeat, The Wall Street Transcript, StockMarketWatch, QualityStocks, MicroCap Gems, Vantage Wire, StocksJournal, Stockhouse and AllPennyStocks reported earlier on Computer Task Group, Inc. (CTG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Corporate Update

Computer Task Group, Inc. (NASDAQ: CTG) was featured in a company-sponsored research note published by Sidoti & Company, LLC. The headline of the note reads, “We Contend CTG’s Valuation Is Attractive, Not Reflective Of The Growing Digital Transformation Market Opportunity We See And The Company’s Positioning On This Front; Maintain $14 Target.”

Click here to access the full report.

About Computer Task Group, Inc.

CTG is a leading provider of digital transformation solutions and services that accelerate clients’ project momentum and achievement of their desired IT and business outcomes. We have earned a reputation as a reliable, results-driven partner focused on improved data-driven decision making, meaningful business performance improvements, new and enhanced customer experiences, and continuous innovation. CTG has operations in North America, South America, Western Europe, and India. Please visit www.ctg.com.

Computer Task Group, Inc. (CTG), closed Thursday’s trading session at $9.25, up 2.4363%, on 40,490 volume. The average volume for the last 3 months is 40,490 and the stock's 52-week low/high is $6.04/$11.68.

Astra Energy Inc. (ASRE)

We reported earlier on Astra Energy Inc. (ASRE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Astra Energy (OTC: ASRE), a renewable and waste-to-energy project developer and technology acquisition company, today announced initiation of joint ventures to develop and deploy energy transformation opportunities to meet Africa’s rising demands for modern renewable energy sources. The company is taking significant steps to achieve its vision to develop clean energy projects that empower communities, protect the environment and shape a sustainable energy landscape for future generations. As part of its market penetration strategy, Astra has entered memorandums of understanding in joint ventures with M&E Associates, one of Uganda’s biggest and most experienced local engineering consulting firms, and Muttico Technical Services Ltd., a large, local high voltage powerline and substation construction and maintenance contractor. Through these joint ventures, the two companies will benefit from Astra’s ability to raise affordable project financing as well as its team of highly experienced technical personnel gathered to successfully propel the projects forward.

To view the full press release, visit https://ibn.fm/QgOEo

About Astra Energy Inc.

Astra Energy is an emerging company in project development and renewable energy technology. The company invests in and develops renewable and clean energy projects in markets where demand is high, supply is limited and there is opportunity to address other imminent market needs, while cultivating a portfolio of intellectual property and global licenses for innovative renewable energy technology and generating projects to deploy that technology. Astra’s corporate strategy is rooted in securing technologies and assets; identifying viable market opportunities; and bringing together resources, expertise, technology and defined action plans to execute first-in-class projects that benefit communities, local economies, the planet and the company’s investors. For further information about Astra Energy, please visit the company’s website at www.AstraEnergyInc.com.

Astra Energy Inc. (ASRE), closed Thursday’s trading session at $0.9, even for the day. The average volume for the last 3 months is 10 and the stock's 52-week low/high is $0.015/$2.00.

Northern Oil and Gas Inc. (NOG)

Wall Street Resources, Investor Relations, MarketBeat, InvestorPlace, Zacks, News Desk, Energy and Capital, MarketClub Analysis, Wyatt Investment Research, VectorVest, StockMarketWatch, Kiplinger Today, The Street, Wealth Insider Alert, QualityStocks, Schaeffer's, Marketbeat.com, Trades Of The Day, Wealth Daily, Greenbackers, Investors Alley, Hit and Run Candle Sticks, StreetInsider, Daily Trade Alert, Investment House, TheStockAdvisors, Wall Street Grand, Trade of the Week, William Velmer, SmarTrend Newsletters, Market Intelligence Center Alert, Rick Saddler, Profit Confidential, prnewswire, Investor News Source, DrStockPick, CustomerService, CRWEWallStreet, CRWEPicks, CRWEFinance, CrashTrade, Complete Growth Investor, ChartAdvisor, BUYINS.NET, Bull Ventures, BestOtc, BestChartNow, Daily Markets, Street Insider, WealthMakers, Trading Concepts, TopStockAnalysts, TheStockAdvisor, The Trading Report, The Stock Enthusiast, Super Stock Picker, Streetwise Reports, PennyOmega, StreetAuthority Daily, Investor Spec Sheet, StockTwits, StocksEarning, StockHotTips, StockBlogs, PennyToBuck, Barchart, Netcom, Market FN, iStockAnalyst and StreetAuthority Financial reported earlier on Northern Oil and Gas Inc. (NOG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Northern Oil and Gas (NYSE American: NOG) recently announced pricing of its underwritten public offering of 10,000,000 shares of its common stock, including 9,500,000 shares offered by the company and 500,000 shares offered by Cresta Investments LLC and Cresta Greenwood LLC (collectively, the “selling stockholders”), at a price to the public of $20.00 per share. The company granted underwriters a 30-day option to purchase up to an additional 1,500,000 shares. Northern Oil and Gas will not receive any proceeds from any sale of shares by the selling stockholders, whose participation in the offering is driven solely by tax planning purposes. According to the update, 100% of proceeds received by selling stockholders from the offering will be used for charitable purposes. Roth Capital Partners acted as co-manager for the offering, which closed on Nov. 22, 2021.

To view the full press release, visit https://ibn.fm/K5jUl

About Northern Oil and Gas Inc.

Northern Oil and Gas is a company with a primary strategy of investing in non-operated minority working and mineral interests in oil and gas properties, with a core area of focus in the premier basins within the United States. For more information about the company, visit www.NorthernOil.com.

Northern Oil and Gas Inc. (NOG), closed Thursday’s trading session at $20.45, off by 1.3983%, on 768,344 volume. The average volume for the last 3 months is 752,180 and the stock's 52-week low/high is $8.05/$27.87.

The QualityStocks Company Corner

FingerMotion Inc. (OTCQX: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (OTCQX: FNGR) .

  • Rich communication services (“RCS”) provider and big data analysis solutions developer FingerMotion has announced an agreement with Munich Re to form a collaborative research alliance to benefit life and health insurance risk evaluation 
  • FingerMotion focuses its SMS, MMS, and big data products on China’s huge high-end phone consumer market 
  • The company’s most recent quarterly report noted a 25 percent YOY quarterly growth in revenues attributed to SMS and MMS services
  • The Munich Re agreement follows FingerMotion’s contract earlier this year with Pacific Life Reinsurance to provide big data analytical services for Pacific Life’s insurance operations in China

Communications and big data technology platform builder FingerMotion (OTCQX: FNGR) is continuing to build reinsurance industry opportunities for its Sapientus data analysis platform, announcing Dec. 6 that its 99 percent-owned subsidiary Shanghai JiuGe Information Technology Co., Ltd. inked a collaborative research alliance with global reinsurance powerhouse Munich Re to improve understanding of morbidity and behavioral patterns in China’s marketplace, focusing on life and health insurance. 

FingerMotion Inc. (OTCQX: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Thursday’s trading session at $5.95, up 9.7786%, on 11,568 volume. The average volume for the last 3 months is 11,568 and the stock's 52-week low/high is $3.22/$17.00.

Recent News

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC)

The QualityStocks Daily Newsletter would like to spotlight BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC).

The cannabis drinks segment has been steadily growing in popularity for the past couple of years. As the cannabis market has matured, players in the cannabis space have been developing a wide variety of products in a bid to capture a part of the massive cannabis market. Cannabis-infused beverages are the latest entrant in the cannabis market. Although the space is only a few years old, the global cannabis beverage market is already projected to be worth $2 billion by 2026. And as those companies enter this coveted segment, they will have to contend with already established cannabis drinks companies such as BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) that are making their presence felt among consumers.

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) is a diversified health & wellness beverage and natural products company focused on developing and manufacturing a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. The BevCanna team boasts decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale.

BevCanna’s distribution network features more than 3,000 points of retail distribution through the company’s market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network and its partnership with #1 U.S. cannabis beverage company Keef Brands.

Based in British Columbia, Canada, BevCanna was founded in 2017.

End-to-End Turnkey Beverage Manufacturing Solutions

BevCanna is a manufacturer of traditional and cannabis-infused beverage brands serving a growing roster of white-label clients, in addition to operating a portfolio of in-house and partner brands. The company offers a full-service white label beverage manufacturing solution.

  • Processing – At its state-of-the-art beverage manufacturing facility, BevCanna partners with industry leaders specializing in crude extraction, refinement, purification and solubility conversion to provide high-quality water-immiscible emulsions that maximize bioavailability, clarity and taste.
  • Spring Water – BevCanna directly owns a pristine naturally alkaline spring water aquifer in British Columbia.
  • Product Development – BevCanna leverages its expertise to develop captivating flavors based on category and consumer insights in order to enhance product positioning.
  • Packaging – A variety of packaging options are offered by BevCanna, including beverage and nutraceutical formats such as PET, aluminum and glass, available in a variety of standard and custom sizes and shapes.
  • Beverage Manufacturing: Traditional & Cannabis Facilities – The company’s 40,000-square-foot beverage manufacturing facility is HACCP (Hazard Analysis Critical Control Point) Certified. The facility’s capabilities include blow molding, dosing, carbonation options, filling and capping, pressure sensitive and shrink-sleeve label applications, flash pasteurization, QA testing and packing/palletizing for shipment.

Pure Therapy, TRACE and Partner Brands

BevCanna’s in-house brands include Pure Therapy and TRACE.

Pure Therapy is a direct-to-consumer e-commerce brand that markets a range of natural health products, including nutraceuticals and hemp-based cannabidiol (CBD) products, throughout North America and Western Europe.

Pure Therapy has secured orders from over 23,000 customers since its inception in 2017. BevCanna expects strong growth through Pure Therapy over the next 12 months driven by new product integration, accelerated growth of existing products and its marketing team’s e-commerce expertise.

TRACE products feature the Naturo Group’s proprietary plant-based fulvic and humic mineral formula, sourced from deep within the Rocky Mountains of interior British Columbia. These unique and ancient minerals provide wellness properties that include iron, magnesium, calcium, potassium and many other minerals no longer found in our food chain at adequate levels.

Research suggests that the proprietary fulvic and humic organic compounds found in TRACE products could offer a number of key benefits, including promoting gut health, immune function, cognitive performance and whole-body wellness.

TRACE products include Natural Alkaline Spring Water, Plant-Based Mineralized Spring Water, Natural Flavor Sparkling Spring Water, Plant-Based Mineral Concentrate with Vitamin D and Plant-Based Mineralized Immune Support Shots.

In addition to its in-house brands, BevCanna provides white-label services to a number of partners in its space. BevCanna’s current portfolio of brand partnerships includes #1 U.S. cannabis beverage brand Keef (cannabis-infused classic soda) and BLOOM (live resin & high-end extracts). BevCanna also has multiple white label agreements to co-manufacture branded beverages.

Market Outlook for Cannabis-Infused Beverages

In 2018, the cannabis-infused beverage market was valued at $901.8 million. The market is expected to grow during the forecast period of 2019 to 2025 at a CAGR of 17.8%, resulting in a market value in excess of $2.84 billion by 2025, according to Grand View Research (https://ibn.fm/VkJfH).

The projected growth is largely attributed to the legalization of recreational and medical marijuana in multiple jurisdictions. Cannabis-infused beverages are uniquely positioned to provide an alternative to a large portion of the edibles market, including items such as chocolates, cookies, gummies and other types of confectionery pieces.

Management Team

Marcello Leone is the CEO and Founder of BevCanna. He is also the founder of Naturo Group and the TRACE brand.

John Campbell is the CFO and CSO of BevCanna. He has over 30 years of experience in the investment industry, including time with TriView Capital Ltd.

Keith Dolo is the company’s Executive Management Advisor, having previously served as CEO and Executive Chairman of Sproutly Inc. Previously, he served for over 13 years with Robert Half (NYSE: RHI), an S&P 500 company, specifically in the role of Vice President for the last eight years.

Melise Panetta is the company’s President. She is an accomplished senior marketing and sales executive with extensive experience leading organizations such as SC Johnson, General Mills (NYSE: GIS) and PepsiCo (NASDAQ: PEP). Ms. Panetta has nearly 15 years of deep marketing and sales expertise.

Raffael Kapusty is the company’s Vice President of Sales & Insights. She is an accomplished CPG industry leader with more than 25 years of experience in both the Canadian and U.S. retail spaces. With a solid foundation at ACNielsen Canada (NYSE: NLSN), Ms. Kapusty has developed a deep understanding of the CPG space, working with over 100 leading Canadian & global CPG manufacturers. She has also held senior category and key account management roles at Kroger (NYSE: KR), SC Johnson and Unilever Canada (NYSE: UL).

Bill Niarchos is the company’s Vice President of Sales & Sales Operations. He has over 20 years of experience in the CPG goods industry/retail environment. In his most recent role as Director of Sales with Bayer Consumer Health, Mr. Niarchos managed the strategic direction and growth of Loblaw & SDM. Prior to his position with Bayer (ETR: BAYN), Mr. Niarchos held a number of progressive roles at Colgate Palmolive (NYSE: CL) for more than 14 years.

Japheth Noah is the company’s Head of Quality Assurance. He is an Oxford and MIT educated quality and regulatory manager with over 15 years of experience in the beverage, pharmaceutical, natural health and medical industries.

Keith Stride is the company’s Creative Director. He has 25 years of experience in marketing and advertising, including time in a CMO role with Hemptown USA. Mr. Stride is internationally recognized for building high-profile brands, including Rogers (NYSE: RCI), TD Bank (NYSE: TD), Best Buy (NYSE: BBY), Whistler-Blackcomb and RBC (NYSE: RY).

BevCanna Enterprises Inc. (OTCQB: BVNNF), closed Thursday’s trading session at $0.1898, up 1.4973%, on 25,169 volume. The average volume for the last 3 months is 25,169 and the stock's 52-week low/high is $0.172/$1.20.

Recent News

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

The QualityStocks Daily Newsletter would like to spotlight Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF).

  • Tryp just announced FDA confirmation for its IND application filed in November 2021
  • The confirmation allows the company to proceed with its Phase 2a study on the effectiveness of psilocybin-assisted therapy among patients with fibromyalgia
  • This clinical study will be one of the first to evaluate synthetic psilocybin for fibromyalgia in a Phase 2 study
  • It is set to commence in 2022 and will involve 20 fibromyalgia patients

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced that it would be proceeding with its upcoming Phase 2a fibromyalgia study, following a confirmation from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/C20cT).

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN™) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

  • Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
  • Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
  • Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN™ Program

Through its PFN™ program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

  • Increased efficacy
  • Natural blood-brain barrier penetration
  • Enhanced safety and toxicity profiles
  • Reduced risk of abuse
  • Reduced risk of addiction

Tryp’s PFN™ program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica®), Duloxetine (Cymbalta®) and Milnacipran (Savella®), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (YPO) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), closed Thursday’s trading session at $0.181, up 0.166021%, on 132,413 volume. The average volume for the last 3 months is 132,413 and the stock's 52-week low/high is $0.173/$1.04.

Recent News

StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF)

The QualityStocks Daily Newsletter would like to spotlight StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF).

The stock price of nickel, zinc and copper rebounded after the decline last week, which was caused by concerns about the new coronavirus variant, omicron. A recent report released by Capital Economics reiterates that prices of these metals will decline significantly as we move into next year. The argument by the London-based independent researcher notes that the weakening of the prices will continue as the economy of China slows but highlights that it’s too soon to know whether the omicron variant will add more pressure. However, Soni Kumari, an analyst at ANZ, notes that if the omicron variant raises serious concerns, this may delay financial tightening, which will in turn be favorable for industrial metals. Copper mining companies such as StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF) can look forward to fairly stable commodity prices despite the discovery of a potentially more lethal COVID-19 variant.

StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF) is a public company engaged in the business of mineral exploration and the acquisition of mineral property assets in North America. The company’s flagship properties are located in the Red Lake Mining District of Ontario, Canada, renowned for over 30 million ounces of historic gold production. Other key projects extend into the neighboring Meen-Dempster Greenstone Belt of the Uchi Subprovince. The company’s management team is led by dedicated professionals, aiming to maximize shareholder value while employing modern exploration techniques and principles to achieve its goals.

The mission of StraightUp Resources is to maximize shareholder wealth through mineral discoveries at projects with robust potential, maintain long-lasting partnerships, and continue to focus on the acquisition, development and exploration of mineral resource properties in North America. The company’s objective is to continue to locate and develop economic, precious and base metal properties of merit.

The company’s 10,000-hectare (almost 25,000 acres) RLX Projects are contiguous to various Evolution Mining, Great Bear Resources, Pacton Gold and Dixie Gold properties. Its 2,000-hectare (just under 5,000 acres) Belanger Project is contiguous to Infinite Ore’s Fredart and Garnet/Arrow properties. StraightUp intends to conduct exploration on the RLX North, RLX South, Belanger and Ferdinand Gold properties located in the Red Lake District, a location touted as having one of the best metal-endowed greenstone belts in the world. The Bear Head Gold Project is located within the Meen-Dempster Greenstone Belt of the Uchi Subprovince, approximately 80 kilometers west of the Pickle Lake Gold Camp and 14 km northeast of the former gold mine, Golden Patricia. It amassed 620,000 ounces of gold at an average of 15.2 g/t Au from 1988-1997. The property is bordered by an Australian miner massive gold project. Known gold occurrences are already mapped on the Bear Head property, as are previous drill holes and results. Once the data is re-examined, an exploration budget and subsequent plans will be announced by the company.

Projects

Ontario’s Red Lake Mining District is one of Canada’s most prolific gold mining districts, renowned for its high-grade gold deposits. This is a mining-friendly, politically stable jurisdiction with a skilled labor force and infrastructure specifically built around meeting the needs of the mining industry.

RLX North & South Projects
At over 10,000 hectares, the RLX North and RLX South Projects represent a district-scale exploration opportunity. The RLX North and RLX South Projects are well positioned on-strike to the southeast of the district’s largest gold deposit (Red Lake Gold Mines – Evolution Mining). The project is adjacent to Great Bear Resources’ Sobel Project. Great Bear Resources is also in the process of evaluating the area for significant regional-scale structural controls and has proposed additional work on its neighboring project in the near term. These properties are highly accessible, with the southern boundary only eight kilometers from the paved highway into Red Lake, and can be accessed by forest service roads which traverse throughout the properties.

Belanger Project
Historic exploration work on the 2,000-hectare property has identified three significant surface exposures of gold, copper and silver. Early exploration work will focus on validating historic sampling results and following the occurrences along strike with a view to better understanding the nature and controls on mineralization. The property has excellent forest road access from the town of Ear Falls.

Ferdinand Gold Project
The Ferdinand property is situated within the southeastern extension of the Confederation-Uchi greenstone belt, one of the most metal-endowed greenstone belts in the world by square kilometer. It consists of 17 contiguous mining claims covering approximately 7,143 hectares (17,650 acres), located 13 kilometers northwest of the town of Slate Falls. Access is currently by logging roads, with forestry logging operations scheduled for expansion on the property. StraightUp recently completed a heliborne magnetic survey consisting of 1,994 line-km at 50m line spacings covering the entire property. The MAG survey was designed to provide geological and structural details of a 25km long southeast extension of the Confederation-Uchi greenstone belt along the Fry-Bamaji Deformation Zone.

Bear Head Gold Project
The Bear Head Gold Project comprises 31 mining claims totaling 1,944 hectares (4,800 acres) in the Meen-Dempster Greenstone Belt of the Uchi Subprovince, host to the Golden Patricia former gold mine, which produced 620,000 ounces of gold from 1988 to 1997. The Dorothy Main gold deposit owned by Ardiden lies only one kilometer from the Bear Head Gold Project. The Dorothy Main gold deposit holds noncompliant historical resources of 46,600 ounces of gold at 6.17 g/t Au. The company looks forward to adding the Bear Head Gold Project to its exploration efforts, with a work program to be conducted later in the fall of 2021.

Management Team

Mark Brezer is CEO, President, and Director of StraightUp Resources Inc. He is a successful businessman and holds a Geography/Geology degree from the University of Arizona. He has worked as a Project Manager and has overseen quality control, environmental monitoring and safety programs related to road construction. He has also held roles in media relations and marketing. He has been actively involved in the research and investment of junior mining companies for over 25 years. Time in the field and personal interest led him into extensive first aid training, and he is certified as a paramedic and firefighter.

Daniel Cruz is CFO and Director at StraightUp Resources. He is an experienced financial industry professional, having worked for 12 years as a senior investment advisor at Canadian broker-dealers, where he gained experience in equity research, asset management, investor relations, corporate finance and venture capital. He was one of the youngest Senior Investment Advisors at Canaccord Financial Inc. in 2010. He is also the co-founder and current director of Liquid Media Group Inc., a Nasdaq-listed issuer. During his tenure as CFO, he helped that company list on Nasdaq and raise over $20 million.

Matthew Coltura is a Director at StraightUp Resources. He has a Bachelor of Business Administration from Okanagan College, where he specialized in finance. He has worked in the finance industry for more than three years. Currently, Mr. Coltura is the CFO of Cayenne Capital Corp. He was also a director of PreveCeutical Medical Inc. from July 2016 to September 2019, a director of Sproutly Canada Inc. (formerly Stoneridge Exploration Corp.) from March 2015 to July 2018, and, since March 2018, has worked as a financial specialist at Quip Finance.

StraightUp Resources Inc. (OTCQB: STUPF), closed Thursday’s trading session at $0.1168, even for the day. The average volume for the last 3 months is 2,499 and the stock's 52-week low/high is $0.10676/$0.26.

Recent News

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF).

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced details regarding Matt Stang, co-founder and CEO of Delic, and his participation at upcoming January events. According to the update, he will present on the company's expansion strategy and industry outlook heading into the new year and offer one-on-one meetings with investors at the HC Wainwright Bioconnect Conference. The virtual event is slated to take place Jan. 10-13, 2022, and feature numerous presenting companies, fireside discussions and meetings with H.C. Wainwright investment banking and research teams. In addition, Stang will host one-on-one meetings that take a closer look at the company's growth opportunities in the upcoming year at CEM's 8th Annual AlphaNorth Capital Conference. Taking place Jan. 21-23, 2022, the conference will be held at the beautiful Grand Hyatt Baha Mar in Nassau, Bahamas, and connect growth-stage companies in sectors including technology and biotech with top-level capital finance individuals. To view the full press release, visit https://ibn.fm/48Xwn. Data from the National Alliance of Mental Health suggests that one in five adults will suffer from a mental health condition in their lifetime. Traditional treatments cause various side effects and can take time to work, which has prompted researchers to seek alternative treatment options for these conditions. Many companies are also conducting R&D activities aimed at commercializing psychedelic treatments for mental health conditions and other indications. Those companies include Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF).

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Inc. (DELCF), closed Thursday’s trading session at $0.14, up 0.143062%, on 12,846 volume. The average volume for the last 3 months is 12,846 and the stock's 52-week low/high is $0.1012/$1.038.

Recent News

ISW Holdings Inc. (OTC: ISWH)

The QualityStocks Daily Newsletter would like to spotlight ISW Holdings Inc. (OTC: ISWH).

ISW Holdings (OTC: ISWH) (transitioning to “BlockQuarry,” pending name change), a Nevada-based portfolio company with primary commercial-stage operations in cryptocurrency mining, today provided an update for current and prospective shareholders. Among the highlights, the company reported that its revenue run rate from its own cryptocurrency mining operations has begun to exceed internal and publicly stated expectations. In addition, phase one of the company’s Southeastern U.S. project to pair 56,000 mining rigs with 200 megawatts of power will soon go live, which will activate 20 MW of power deployed to self-contained cryptocurrency mining pods. Following full deployment and activation of all 200 MW of power at the company’s Southeastern U.S. project, ISWH will have the opportunity to increase its facility to 500 MW of power. The opportunity, which will allow for a significant expansion in hosting and mining potential, ties into the company’s S-1 filing process. “Filing the S-1 was an integral step as we continue to work toward an uplisting to the Nasdaq exchange,” said Alonzo Pierce, president and chair of ISW Holdings. “We are on the verge of activating our phase one hosting operations, and we expect phase two to move rapidly on the heels of that transition. Once we have the entire 200 MW fully deployed, we will have the opportunity to push the ceiling considerably higher. We are also very pleased at the results coming in from Pennsylvania, where our mining efficiency has exceeded expectations.” To view the full press release, visit https://ibn.fm/ahLRE

ISW Holdings Inc. (OTC: ISWH), through its in-house initiatives and strategic partnerships, has invested in growing operations targeting the telehealth and cryptocurrency mining industries.

The company specializes in strategic brand development and early growth facilitation. Management maneuvers its proprietary companies through critical stages of market development, including conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency.

Mission

The company’s core mission is to enhance these sectors by implementing innovative services and products that are ready to meet the demands of a changing world. To that end, ISW Holdings leverages its strategic expertise, resources and innovative software to establish market-leading companies and partnerships, thereby ensuring success in their chosen industries.

Cryptocurrency Mining

The start of 2021 saw a massive resurgence in interest surrounding bitcoin and cryptocurrency mining. In mid-February, bitcoin prices hit an all-time high of greater than $57,000, and heightened demand for cryptocurrency mining power has played a key role in exacerbating a global shortage of semiconductors and computer components.

With a foothold in the cryptocurrency mining space, ISW Holdings has placed significant focus on expanding its position and capitalizing on this momentum. Recent highlights include:

  • February 9, 2021: The company announced that its revolutionary Pod5 Cryptocurrency Mining Pod will be powered up into full operational launch at the Bit5ive renewable energy cryptocurrency mining facility in Pennsylvania on February 12, 2021.
  • February 11, 2021: The company announced that it is in negotiations to purchase a large number of miners (between 300 and 900) in preparation for its coming Phase 3 expansion in mining volume.
  • February 23, 2021: The company announced its entry into a comprehensive Hosting and Maintenance Agreement prior to going online with its new ASIC s17 miners.
  • March 2, 2021: The company announced that it has successfully tripled its active cryptocurrency mining fleet with the addition of two new POD5IVE datacenters.

“As we continue to bring our miners online, we want our shareholders to be able to track the expansion and profitability of the company’s mining activity given the sharp rising trend in bitcoin prices,” Alonzo Pierce, President and Chairman of ISW Holdings, stated in a news release. “It currently costs about $11K in computing power to mine a single bitcoin. Bitcoin is pricing at over five times that level, making this is an exceptional ROI opportunity, and our responsibility to our shareholders is clear: continue to invest, expand and execute.”

Business Innovations

ISW Holdings’ diverse portfolio reflects the growing demand for essential services in a dynamic modern operational landscape. Some of the company’s current holdings and partnerships include:

  • Bit5ive LLC: ISW Holdings operates a joint venture with Bit5ive, a global leader in cryptocurrency mining. The joint-venture agreement enables ISW Holdings to collaborate with the experienced team at Bit5ive to innovate the infrastructure needed to run profitable and efficient crypto mining projects.
  • Proceso LLC: ISW Holdings has partnered with Proceso LLC to create high-density processing and mobile data centers powered by renewable energy. These innovations will allow Proceso to offer lower-cost and diverse services to its clients, including hosting and colocation services to growing sectors such as the gaming industry and cryptocurrency mining.
  • PHH Health: The company’s home health division answers the growing need for home care services in a world where health care delivery is changing and an increasingly large aging community is looking for efficient and effective ways of accessing health care.
  • Volum: The company’s logistics and supply chain management division is designed with the core goal of increasing supply chain efficiency, which is recognized as one of the key aspects of successfully growing any business.

Market Opportunity

ISW Holdings’ recent activity in the cryptocurrency mining sector has positioned it to capitalize on the forecast expansion of the cryptocurrency market in the coming years. According to data from MarketsandMarkets, the cryptocurrency space was valued at $1.03 billion in 2019 and is projected to reach $1.40 billion in 2024, achieving a CAGR of 6.18% during the forecast period.

The report suggests that major drivers for this growth will be the transparency of the underlying blockchain technology, the high volume of remittances in developing countries, the high cost of international remittance, expected fluctuations in monetary regulations and sustained investment in the cryptocurrency space by venture capital firms.

Management Team

Terry Williams is the Chief Executive Officer and Director of ISW Holdings. Mr. Williams brings to the company more than 30 years of experience in accounting and information systems, logistics, insurance and transportation. With a Bachelor’s and Master’s degree in accounting and management information systems, he amassed considerable corporate experience at UPS (NYSE: UPS), where he took several logistical roles, managing more than 2,000 employees and a budget of more than $10 billion. Mr. Williams also serves as president of Airware Transportation and Logistics and Chief Financial Officer of AVI Insurance Caribbean. In 2013, he received the National Airport Minority Advisory Council Award for mastering skills in the aviation industry.

Alonzo Pierce is the company’s President and Chairman. He brings a wealth of business development and wealth management experience to the ISW team, having spent the past 20 years building recognizable brands in multiple industry sectors. Mr. Pierce has launched enterprises in life-styled brands which were delivered to high-profile, high-net worth families and individuals. He has worked in the adult beverage industry, establishing a formidable background in marketing and brand creation. Pierce has a B.A. from Baylor University and has received multiple awards in the adult beverage industry, including ‘Outstanding Sales Performance in the Southern Region’ for Sapphire Brands. Pierce also served as a national liaison to a Super-Regional Bank’s private wealth division. In addition to his for-profit endeavors, Pierce has served on multiple charitable boards, sourcing funding for JRA, food insecure families and housing insecure families.

Kristina Mahoney-Brown is Secretary, Treasurer and Director of ISW Holdings. With more than 20 years of experience providing tax and financial consulting to real estate companies, as well as investors, developers and construction companies, Ms. Mahoney-Brown has gained solid business expertise and market knowledge and prides herself on staying abreast of the latest industry trends. Her professionalism, impeccable work ethic and advanced marketing strategies have earned her the nickname ‘The Tax Diva’. Mahoney-Brown has a Bachelor’s in accounting, a Master’s in taxation and a Master’s in business administration, specializing in personal financial planning.

ISW Holdings Inc. (ISWH), closed Thursday’s trading session at $1.4, even for the day, on 303,261 volume. The average volume for the last 3 months is 303,261 and the stock's 52-week low/high is $0.0496/$3.78.

Recent News

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF)

The QualityStocks Daily Newsletter would like to spotlight Avricore Health Inc. (OTCQB: AVCRF).

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) has, since the company’s inception, been driven by the development of a network of point-of-care (“POC”) analyzers that run on its HealthTab(TM) software in community pharmacies, workplaces and rural areas. Earlier this year, the company signed a deal with Abbott to expand the distribution of its Affinion 2 analyzers in pharmacies. Shortly thereafter, Avricore also entered an agreement with Shoppers Drug Mart to stock HealthTab for diabetes screening in 11 different locations. “The company has recognized an opportunity and capitalizes on established consumer trends, technology advancements, health policy and industry changes to solve a business headache while also meeting a significant market opportunity. All this is built on the company’s HealthTab platform,” reads a recent article. “So far, HealthTab can check up to 27 health markers, screen diabetes and conduct rapid Covid-19 testing. It also offers convenience, with analyses taking less than 10 minutes…. The milestones achieved with HealthTab so far are significant. More so, they highlight the endless possibilities that the platform has regarding the diagnosis of various chronic diseases, bacteria and viruses.” To view the full article, visit https://ibn.fm/7pkpk

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab™ (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

HealthTab

HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets and third-party app integration through API.

Agreement with Shoppers Drug Mart

In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2™ analyzers provided by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near Term Goals

Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies.

Market Outlook

In 2020, the global point-of-care testing (POCT) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (CAGR) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Management Team

Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia.

Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia.

Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Avricore Health Inc. (OTCQB: AVCRF), closed Thursday’s trading session at $0.10685, even for the day. The average volume for the last 3 months is 5 and the stock's 52-week low/high is $0.068/$0.48562.

Recent News

reAlpha

The QualityStocks Daily Newsletter would like to spotlight reAlpha

reAlpha, a cutting-edge technology company empowering everyone to invest in the $1.2 trillion short-term rental market, is proud to announce its new partnership with Title First Agency, one of the largest independent title agencies in the nation. The partnership with Title First will allow reAlpha to simplify and streamline its large-scale property acquisition process. Title First Agency is a nationwide resource for title insurance and real estate settlement services. As a newly acquired division of Stewart Title, they have a footprint in every state and metropolitan area in the United States, in addition to 20 other countries.

reAlpha is the Robinhood of Airbnb investments, representing the intersection of modern technology and lasting assets. A new wave of investment opportunities in real estate has emerged, and Airbnb short-term rentals are changing hospitality and travel on a global scale. Previously, only accredited investors have had access to the best real estate deals, but reAlpha is democratizing this lucrative new model, empowering anyone to generate wealth as a reAlpha member. reAlpha uses its proprietary, disruptive technologies to level the playing field, unraveling the industry’s high barriers to entry and bringing the power of real estate investing to the “99 percent.”

The company’s unique model allows investors to benefit from both the superior returns of short-term rental income and increases in property value through renovation and appreciating markets. reAlpha likens this double investment return to seeing two desserts on a dinner menu and ordering both.

The company seeks to open up access to real estate investing by letting regular people buy fractional ownership of short-term rentals using reAlpha’s smartphone app. The reAlpha app simplifies the real estate investing process. In the app, investors can check out the company’s most current properties offered for investment. If they choose to invest, they become members of a syndicate invested in a specific short-term rental property. Syndicate members receive quarterly dividend payments from rental revenue generated by the property in which they invested. The reAlpha model merges the most historically stable asset – real estate – with technology and the sharing-economy business model of the future – Airbnb.

The company handles all property management functions and believes short-term rentals are no longer purely transactional and occupancy-driven. reAlpha reimagines the entire guest experience end-to-end to make sure the reAlphaHouse is the ultimate on-demand rental property. The company plans to implement various technologies, including smart locks, voice-activated electronics, home automation systems, and innovative furnishings, to create an unparalleled guest experience. When guests have exceptional stays, investors enjoy maximized profits.

How it Works

reAlpha has identified specific markets in which to purchase short-term rentals across the globe. The company prefers to buy 100 to 500 properties in each market. reAlpha uses artificial intelligence technology, dubbed reAlphaBRAIN, to select “unicorn properties,” the best available opportunities in the market for investment. The AI software can quickly evaluate thousands of property listings based on 25+ factors and assign each a reAlphaScore, projecting how Airbnb Viable the property is, as well as its projected value in the housing market.

For a minimum investment of $2,500, an investor can purchase equity in a specific reAlpha property, similar to how they would buy stock or shares in a company. reAlpha matches the investor with other like-minded backers to form a syndicate, so together they can cover a down payment on the selected property. Investment properties usually require a down payment of 25 percent of the purchase price, but, with reAlpha properties, the down payment is only 10 percent because of the company’s relationships with lenders, making the initial investment more affordable.

reAlpha maintains a majority stake in each investment syndicate, retaining 51 percent ownership in each purchased property and ensuring their interests are always aligned with investing members. Properties are typically refinanced after 12 to 16 months, freeing equity for reinvestment in additional properties. The company uses its AI software to predict optimum timing to sell properties in order to extract maximum value for investors. Gains are reinvested in additional properties. However, reAlpha also believes that real estate investing is more than financial returns. It includes the pride of ownership and the freedom of financial security. reAlpha members have access to their property when it is not rented out on Airbnb. The company is driven every day to create not only lucrative returns for its members but also to deliver exceptional experiences and positive impact in the communities in which reAlpha lives and operates.

 

Market Outlook

There are an estimated 7.4 million short-term rental properties worldwide. The total asset value of this global market is projected at $1.2 trillion. In the U.S. there are about 1.8 million short-term rental properties. These have an estimated asset value of $933 billion. Brain Chesky, the CEO of Airbnb, recently stated that there is a shortage of properties to meet demand and that the company will need “millions of more hosts.” reAlpha is projecting that the company and its investors will own 5,000 short-term rental investment properties by 2025. reAlpha forecasts annual revenue of $434 million by 2025.

Management Team

Giri Devanur is the CEO and co-founder of reAlpha. Prior to founding reAlpha, he served as president and CEO of enterprise software company Ameri100 Inc. from its founding in 2013. He scaled Ameri100 from zero to $50 million in revenue and took the company public in 2017. That same year, he was named E&Y Entrepreneur of the Year. He immigrated to the U.S. with virtually no possessions and $65 in the bank. He earned a Master’s in Technology Management from Columbia University, where he continues to mentor aspiring entrepreneurs.

Monaz Karkaria is the COO and co-founder of reAlpha. Prior to reAlpha, she founded real estate management firm Ben Zen Properties LLC. She has also worked in branch operations for Citibank. Before her involvement in Citibank, she worked at Berlitz in Sao Paulo, Brazil, as an ESL business coach and consultant for various international business clients like GE, Google, PepsiCo and others. She began her career in sales and marketing at Smith & Nephew Dubai. She is also a popular real estate coach and speaker.

Mike Logozzo is the CFO of reAlpha. Prior to joining the company, he served as Managing Director, Americas for innovation advisory firm L Marks. Before that, he was General Manager, Financial Services Operations, Americas Region for BMW Group Financial Services, where he also held Special Projects Manager and CIC Strategy Manager positions.

Christie Currie is the CMO of reAlpha. Previously, Christie launched her own business in the MedTech space, Zandaland, where she worked closely with large enterprises and health care systems. Currie’s work in the startup community led her to London-based corporate innovation firm L Marks, where she led world-leading corporations in retail, supply chain and logistics, and health care to identify strategic areas of need and successfully engage industry-disrupting startups. Currie has mentored hundreds of these startups, helping them to align their technology solutions with market needs.


Recent News

chart

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following the acquisition of BayMedica Inc. in October that created an industry leader in the manufacture and commercialization of rare cannabinoids, management expects to introduce multiple new, rare cannabinoids in the near future, focusing on high demand, attractive margin products. In late September, InMed commenced the 755-201-EB study, its phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders scientifically known as Epidermolysis Bullosa (“EB”). A recent article reads, “The commencement of the study marked the first time cannabinol has advanced to a phase 2 clinical trial to be evaluated as a therapeutic option for disease treatment… InMed has also developed a cannabinol (‘CBN’) topical eye drop formulation currently the subject of preclinical studies as a potential treatment for glaucoma… InMed continues to work toward completing the INM-088-based preclinical studies in preparation for human clinical trials. The company anticipates filing regulatory applications in the second half of the 2022 financial year to commence human clinical testing with INM-088.” To view the full article, visit: https://ibn.fm/UY4q0.

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Thursday’s trading session at $1.54, off by 3.75%, on 132,769 volume. The average volume for the last 3 months is 132,718 and the stock's 52-week low/high is $1.2545/$6.42.

Recent News

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC)

The QualityStocks Daily Newsletter would like to spotlight AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC).

Most patients put off going to the doctor or skipped undergoing checkups because of the coronavirus pandemic last year. Despite infection cases dropping and vaccine rollout, data analytics still show a considerable drop in CT imaging for cancer. Researchers from Harvard Medical School and Massachusetts General Hospital conducted an analysis of CT exams for cancer that were conducted last year, both during the precoronavirus phase and the peak coronavirus phase, as well as in the post-coronavirus peak phase. Much can be done to encourage people to resume their cancer screening, especially given that companies such as AnPac Bio-Medical Science Co. Ltd. (NADAQ: ANPC) are focused on bringing to market the latest and most cost-effective cancer screening technologies so that people can get onto treatment sooner once a positive diagnosis is confirmed.

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection. The company develops, distributes and deploys accessible early disease detection devices with an aim of changing the way people approach cancer screening. AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance.

AnPac Bio-Medical has clinical laboratories in the United States and China, with 142 issued patents as of March 31, 2021. Its corporate headquarters is located in Shanghai, China, while its U.S. headquarters is situated in Philadelphia, Pennsylvania. The company operates two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States.

Cancer Differentiation Analysis (CDA)

Cancer Differentiation Analysis (CDA) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form.

Most liquid-based cancer screening and detection technologies focus on biochemical signals, like conventional biomarkers and genomic signals, such as ct-DNAs and CTCs (circulating tumor cells in the blood). These typically only determine whether or not cancer has occurred at a fixed point in time.

CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future – all through a standard blood test, at a competitive price point.

AnPac Bio-Medical’s CDA is powered by a database of over 200,000 samples and cases and serves as a new way to approach disease and cancer screening. The device uses an integrated system of sensors to detect several biophysical signals at the cellular, protein and molecular levels. CDA leverages a proprietary algorithm to synthesize the data, effectively generating a personalized risk assessment for evaluated patients.

Through CDA technology, AnPac Bio-Medical aims to address a number of goals, including:

  • Innovate – AnPac Bio-Medical is an innovator in the cancer screening industry, with CDA research ongoing since 2008, and commercial operations beginning in 2015. AnPac considers itself a thought leader in developing multi-cancer screening.
  • Detect – AnPac Bio-Medical detects early signals of threatening cancer and its location within the body.
  • Identify – CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity rates.
  • Provide – The company’s platform provides multi-level, multi-parameter analysis using proprietary diagnostic algorithms, which results in accurate and easy-to-understand results.
  • Proven – A fully operational analysis of over 200,000 test samples has been run to date. CDA technology has been shown to identify pre- and early-stage cancers in patients previously diagnosed as “cancer-free” through traditional methods.
  • Biophysical Properties – CDA analyzes biophysical properties in human blood and the correlation between biophysical properties and cancer occurrence.

Market Outlook

AnPac Bio-Medical is exploring detection of other types of cancers leveraging its innovative CDA technology and multi-cancer screening and detection tests, which could open significant opportunities on the global cancer diagnostics market.

According to a report by Grand View Research, the cancer diagnostics market is expected to reach $249.6 billion worldwide by 2026 (https://nnw.fm/L7css). The market is expected to grow at a CAGR of 7% during the forecast period.

Management Team

Dr. Chris Yu is the Co-Founder and Chief Executive Officer of AnPac Bio-Medical. He has enjoyed a successful career as an innovator in life sciences, technology and engineering. Dr. Yu has worked for three U.S. Fortune 500 companies and is the first/principal inventor of over 300 patent applications spanning semiconductors, materials and life science. He has a proven history of developing cutting-edge products with long-term profit and sustainability. Dr. Yu was born to a medical doctor’s family and went to medical school. He later switched his major to physics and received his bachelor’s and master’s degrees in physics from the University of Missouri-Kansas City Campus and a doctoral degree in physics from Pennsylvania State University. Both of his dissertations addressed innovative detection techniques.

Dr. Herbert Yu is the Co-Founder and Chief Medical Officer of AnPac Bio-Medical. He is a renowned expert in molecular epidemiology, with training in medicine and chemical biochemistry. Dr. Yu has a 20-year career in leading-edge cancer research, including breakthrough work in areas of carcinogenic factors. He is a professor and research director at the University of Hawaii and an adjunct professor at Yale University. He received his bachelor’s degree in medicine from Shanghai First Medical College. Dr. Yu also received a science degree in epidemiology and a Ph.D. in clinical biochemistry from the University of Toronto.

Jingiu (Edward) Tang is the company’s Chief Financial Officer. He previously served as a global internal auditor at Natuzzi S.p.A. Mr. Tang also worked at Beijing Dongshen CPA and Shanghai De’an CPA, providing external audits, finance and tax advisory services across different industries and sectors. He is a Certified Public Accountant in Australia. Mr. Tang received his bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University, and his bachelor’s degree in law from Southwest University of Science and Technology in China.

Weidong Dai is the company’s China General Manager. He previously served as a general partner at Stirrfir Investment Management Co. Mr. Dai has also served as the chairman of RTS Management (Shanghai) Co., and as managing director of Hong Kong Pro-Health Technology Co. and Shanghai Pro-Health Medical Devices Co. He has published a number of medical research papers and research articles in professional journals. Mr. Dai was awarded the Hong Kong Industrial Award for a medical device that he led in research and development. He earned his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from the Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics.

AnPac Bio-Medical Science Co. Ltd. (ANPC), closed Thursday’s trading session at $1.29, off by 1.5267%, on 351,575 volume. The average volume for the last 3 months is 351,575 and the stock's 52-week low/high is $1.15/$12.09.

Recent News

DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF)

The QualityStocks Daily Newsletter would like to spotlight DigiMax Global Inc. (CSE: DIGI) (OTCQB: DBKSF).

DigiMax Global (CSE: DIGI) (OTC: DBKSF), a company that provides artificial intelligence (“AI”) and cryptocurrency technology solutions, is poised to benefit from the fact that AI technology may just be what companies need to make decisions on hiring the right talent and personality for a job. DIGI’s Projected Personality Interpreter (“PPI”), which was originally conceived and launched by Darwin Ecosystems, a company that was acquired by DigiMax late last year, evaluates a company’s workforce, brand and culture by revealing the personality traits and sentiments buried in human expression. “By leveraging IBM Watson and a customer algorithm that analyzes applicant responses across 52 different traits and compares those scores with a baseline, PPI can provide HR personnel with complete information that supports and guides decision making and removes bias. With PPI, savvy organizations can make better hiring decisions, reduce employment attrition and improve workplace culture,” reads a recent article. “Employers aren’t the only ones that can use PPI. The platform is available as an app, enabling users to identify the personality projected by their social media footprint as well as blogs and web pages. Users can even submit student essays, research papers, work reports and executive summaries to measure the personality traits projected.” To view the full article, visit https://ccw.fm/XHQt0

DigiMax Global Inc. (CSE: DIGI) (OTCQB: DBKSF) is an artificial intelligence technology and services company producing and leveraging predictive indicators across various industries and verticals.

The company offers financial, business, and human capital AI predictive solutions to businesses, institutions, and consumers to improve decision-making.

The DigiMax core solutions are:

  1. CryptoHawk AI – CryptoHawk is a deep learning AI solution (SaaS) that monitors and analyzes live select cryptocurrencies and financial markets. The CryptoHawk AI solution is offered to retail clients as a monthly subscription. Generated data provides subscribers with price trend predictions for better investment strategies.
  2. Cryptocurrency Hedge Fund – A long/short cryptocurrency hedge fund for high net worth, institutional, and family office clients was launched on September 1, 2021. The company’s crypto hedge fund earns clients’ management and overall performance fees.
  3. Projected Personality Interpreter (PPI) – DigiMax solutions utilize AI to provide comparative insights for better hiring decisions, reduced employment attrition, improved workplace culture, and augmented human and financial predictive services by measuring and correlating personal attributes.
  4. Navee Predict – DigiMax data scientists provide companies with the unprecedented power of enhancing decision-making by analyzing, detecting changes and forecasting patterns.

The company’s team has extensive experience in finance, trading, machine learning (ML), neural language processing, AI, big data, and cryptocurrency technology. DigiMax leverages AI and its expert team to translate data into actionable predictive insights across the financial, business, and human dimensions, enhancing the decision-making capacity of organizations. DigiMax is an official IBM Watson partner with more than 30 years in data science and artificial intelligence.

Solutions

Business and Financial Capital Solutions

CryptoHawk AI

CryptoHawk.ai is a cryptocurrency price and trend prediction solution offered as a web application (https://cryptohawk.ai) and a mobile application by the end of 2021. The value for the user is to capture gains and take advantage of volatility while reducing risk and engaging in smarter and simpler trading.

The key features:

  • Trend Prediction Indicator (“TPI”)
    The TPI is a superior model that leverages the cryptocurrencies analyzed by the AI and other market-driven data and policies to produce actionable predictions in the form of:
    • Prediction cards
    • Cryptocurrency graphs with optional market indicators
    • Email/SMS alerts
  • Trend Watch
    Trend Watch is a one-week look ahead machine learning prediction for a select portfolio of mature cryptocurrencies. Trend Watch predicts a trend being UP or DOWN and provides a price target. Users have access to:
    • A list of select cryptocurrencies with predictive graphs

The system alerts investors through email and text messages when a price trend changes, allowing users to act confidently.

Cryptocurrency Hedge Fund

On September 1, 2021, DigiMax launched its Cryptocurrency Hedge Fund to offer high net worth, institutional, and family office clients a fully systematic long/short active investment into a basket of cryptocurrencies capitalizing on crypto volatility and powered by proprietary trading algorithms. The official launch is expected in the coming months.

The fund is led by 40-year hedge fund veteran Ian Hamilton and has an experienced investment and fund management team. This actively managed fund provides an excellent opportunity for larger investors to gain exposure to cryptocurrencies.

AI Business Prediction as a Service

The company offers predictive insights to businesses through automation and its innovative and proprietary AI and ML technology. Traditional models are expensive, because they are created and developed by data scientists dedicated to solving specific business questions that require costly customization and weeks, if not months, of development. With DigiMax, companies have access to solutions and services at a fraction of the price of traditional and experimental approaches. By combining AI with ML prediction technology, the company delivers insights on:

  • Sales forecasts
  • Optimal inventory levels
  • Supply chain management
  • Invoice payment projections
  • Targeted segmentation for marketing campaigns

Human Capital Solutions

AI-Powered Projected Personality Interpreter

The Projected Personality Interpreter (“PPI”) evaluates and improves customers’ workforce, brand and culture by revealing the personality traits and sentiment buried in human expression. The PPI empowers organizations with comparative insight for better hiring decisions, reducing employment attrition and improving workplace culture.

PPI provides a comprehensive and complete solution, offering:

  • Recruitment campaign management
  • Custom questionnaires, desirable traits recipes, and group likenesses
  • Detailed personality reports to compare and contrast peers
  • API for advanced integration with alternative systems of record

DigiMax leverages IBM Watson and a custom algorithm that analyzes applicant responses across 52 different traits and compares those scores with a baseline, providing hiring managers with a comprehensive report that improves decision making and takes the bias out of the process. The company’s solution is currently in use by 17 law enforcement agencies in North America and is used across the 10 global recruitment brands of Shepherd Search Group.

Market Overview

The AI industry has a five-year CAGR of 18.4%, with revenues projected to reach $37.9 billion by 2024. Some more optimistic forecasts have the market worth as much as $15 trillion by 2030. It’s estimated that 80% of all emerging technologies in 2021 have AI foundations. About 40% of all businesses use AI in their operations. According to Industry Ark, artificial intelligence use in the recruitment market was valued at $580 million in 2019.

Management Team

Chris Carl, CEO

Chris Carl has over 20 years of experience as a public-company CEO and has built several successful businesses across multiple categories. He has a proven ability to lead and has a track record of execution, revenue growth, and value creation.

Thierry Hubert, CTO

Thierry Hubert has 30 years of technology experience with Fortune 100 companies worldwide and is an early pioneer in applying artificial intelligence to solve big data and unstructured information challenges with IBM as a Director of R&D in emerging technology, knowledge management, and process innovation. He has received awards, recognitions, and grants that contributed to his ongoing collaboration with industry leaders.

David Bhumgara, CFO

David Bhumgara is a senior finance executive with over 25 years of leadership experience and proven expertise in finance, financial reporting, accounting, corporate finance, budgeting, financial modeling, and mergers & acquisitions.

Damon Stone, Trading Strategy Advisor

Damon Stone is an experienced stock and crypto trader who works very closely with the Cryptodivine.ai data science team as a subject matter expert. During 15 years at Merrill Lynch as a market maker and proprietary trader, he traded many different sectors, culminating in heading up a $250 million trading desk.

Ross Power, Senior Innovation Engineer
Ross Power is an experienced technical system architect with a demonstrated history of working on advanced technologies, including AI algorithms, IoT solutions, 3D printing, Innovation in BCI (Brain-Computer Interfacing), and RC flight and navigation systems.

DigiMax Global Inc. (DBKSF), closed Thursday’s trading session at $0.059, off by 7.5235%, on 17,000 volume. The average volume for the last 3 months is 17,000 and the stock's 52-week low/high is $0.05/$0.70.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

  • Company receives grant to fund clinic for marginalized, underserved NYC communities
  • New clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the service
  • Program’s clinicians will receive specialized training

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital (https://ibn.fm/zyerA).

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Thursday’s trading session at $1.21, off by 4.7244%, on 1,680,972 volume. The average volume for the last 3 months is 1.668M and the stock's 52-week low/high is $0.8943/$3.38.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading